 | • レポートコード：MRC23Q35799 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、84ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の毛細血管拡張性運動失調症（AT）治療市場について調査・分析し、世界の毛細血管拡張性運動失調症（AT）治療市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（内服錠、注射剤）、用途別セグメント分析（病院、薬局、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Sanofi、Intrabio Ltd、Intas Pharmaceuticals Ltd、Sun Pharmaceutical Industries Ltd、Cipla Inc、Eli Lilly and Company、Saol Therapeutics Inc、USV Private Limitedなどが含まれています。世界の毛細血管拡張性運動失調症（AT）治療市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、毛細血管拡張性運動失調症（AT）治療市場規模を推定する際に考慮しました。本レポートは、毛細血管拡張性運動失調症（AT）治療の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、毛細血管拡張性運動失調症（AT）治療に関するビジネス上の意思決定に役立てることを目的としています。 ・毛細血管拡張性運動失調症（AT）治療市場の概要 - 毛細血管拡張性運動失調症（AT）治療のタイプ別セグメント - 世界の毛細血管拡張性運動失調症（AT）治療市場規模：タイプ別分析（内服錠、注射剤） - 毛細血管拡張性運動失調症（AT）治療の用途別セグメント - 世界の毛細血管拡張性運動失調症（AT）治療市場規模：用途別分析（病院、薬局、その他） - 世界の毛細血管拡張性運動失調症（AT）治療市場規模予測（2018年-2029年） ・毛細血管拡張性運動失調症（AT）治療市場の成長トレンド - 毛細血管拡張性運動失調症（AT）治療の地域別市場規模（2018年-2029年） - 毛細血管拡張性運動失調症（AT）治療市場ダイナミクス - 毛細血管拡張性運動失調症（AT）治療の業界動向 - 毛細血管拡張性運動失調症（AT）治療市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：内服錠、注射剤 - 世界の毛細血管拡張性運動失調症（AT）治療のタイプ別市場規模（2018年-2023年） - 世界の毛細血管拡張性運動失調症（AT）治療のタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院、薬局、その他 - 世界の毛細血管拡張性運動失調症（AT）治療の用途別市場規模（2018年-2023年） - 世界の毛細血管拡張性運動失調症（AT）治療の用途別市場規模（2024年-2029年） ・毛細血管拡張性運動失調症（AT）治療の地域別市場規模 - 北米の毛細血管拡張性運動失調症（AT）治療市場規模（2018年-2029年） - アメリカの毛細血管拡張性運動失調症（AT）治療市場規模（2018年-2029年） - ヨーロッパの毛細血管拡張性運動失調症（AT）治療市場規模（2018年-2029年） - アジア太平洋の毛細血管拡張性運動失調症（AT）治療市場規模（2018年-2029年） - 中国の毛細血管拡張性運動失調症（AT）治療市場規模（2018年-2029年） - 日本の毛細血管拡張性運動失調症（AT）治療市場規模（2018年-2029年） - 韓国の毛細血管拡張性運動失調症（AT）治療市場規模（2018年-2029年） - インドの毛細血管拡張性運動失調症（AT）治療市場規模（2018年-2029年） - オーストラリアの毛細血管拡張性運動失調症（AT）治療市場規模（2018年-2029年） - 中南米の毛細血管拡張性運動失調症（AT）治療市場規模（2018年-2029年） - 中東・アフリカの毛細血管拡張性運動失調症（AT）治療市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Sanofi、Intrabio Ltd、Intas Pharmaceuticals Ltd、Sun Pharmaceutical Industries Ltd、Cipla Inc、Eli Lilly and Company、Saol Therapeutics Inc、USV Private Limited ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Ataxia-telangiectasia (AT) Treatment market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Ataxia-telangiectasia (AT) Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Ataxia-telangiectasia (AT) Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Ataxia-telangiectasia (AT) Treatment in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Ataxia-telangiectasia (AT) Treatment include Sanofi, Intrabio Ltd, Intas Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Cipla Inc, Eli Lilly and Company, Saol Therapeutics Inc and USV Private Limited, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Ataxia-telangiectasia (AT) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ataxia-telangiectasia (AT) Treatment.
The Ataxia-telangiectasia (AT) Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Ataxia-telangiectasia (AT) Treatment market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Ataxia-telangiectasia (AT) Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Sanofi
Intrabio Ltd
Intas Pharmaceuticals Ltd
Sun Pharmaceutical Industries Ltd
Cipla Inc
Eli Lilly and Company
Saol Therapeutics Inc
USV Private Limited
Segment by Type
Oral tablets
Injections
Segment by Application
Hospital
Pharmacy
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Ataxia-telangiectasia (AT) Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Ataxia-telangiectasia (AT) Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Oral tablets
1.2.3 Injections
1.3 Market by Application
1.3.1 Global Ataxia-telangiectasia (AT) Treatment Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Ataxia-telangiectasia (AT) Treatment Market Perspective (2018-2029)
2.2 Ataxia-telangiectasia (AT) Treatment Growth Trends by Region
2.2.1 Global Ataxia-telangiectasia (AT) Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Ataxia-telangiectasia (AT) Treatment Historic Market Size by Region (2018-2023)
2.2.3 Ataxia-telangiectasia (AT) Treatment Forecasted Market Size by Region (2024-2029)
2.3 Ataxia-telangiectasia (AT) Treatment Market Dynamics
2.3.1 Ataxia-telangiectasia (AT) Treatment Industry Trends
2.3.2 Ataxia-telangiectasia (AT) Treatment Market Drivers
2.3.3 Ataxia-telangiectasia (AT) Treatment Market Challenges
2.3.4 Ataxia-telangiectasia (AT) Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Ataxia-telangiectasia (AT) Treatment Players by Revenue
3.1.1 Global Top Ataxia-telangiectasia (AT) Treatment Players by Revenue (2018-2023)
3.1.2 Global Ataxia-telangiectasia (AT) Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Ataxia-telangiectasia (AT) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Ataxia-telangiectasia (AT) Treatment Revenue
3.4 Global Ataxia-telangiectasia (AT) Treatment Market Concentration Ratio
3.4.1 Global Ataxia-telangiectasia (AT) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Ataxia-telangiectasia (AT) Treatment Revenue in 2022
3.5 Ataxia-telangiectasia (AT) Treatment Key Players Head office and Area Served
3.6 Key Players Ataxia-telangiectasia (AT) Treatment Product Solution and Service
3.7 Date of Enter into Ataxia-telangiectasia (AT) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Ataxia-telangiectasia (AT) Treatment Breakdown Data by Type
4.1 Global Ataxia-telangiectasia (AT) Treatment Historic Market Size by Type (2018-2023)
4.2 Global Ataxia-telangiectasia (AT) Treatment Forecasted Market Size by Type (2024-2029)
5 Ataxia-telangiectasia (AT) Treatment Breakdown Data by Application
5.1 Global Ataxia-telangiectasia (AT) Treatment Historic Market Size by Application (2018-2023)
5.2 Global Ataxia-telangiectasia (AT) Treatment Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Ataxia-telangiectasia (AT) Treatment Market Size (2018-2029)
6.2 North America Ataxia-telangiectasia (AT) Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Ataxia-telangiectasia (AT) Treatment Market Size by Country (2018-2023)
6.4 North America Ataxia-telangiectasia (AT) Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Ataxia-telangiectasia (AT) Treatment Market Size (2018-2029)
7.2 Europe Ataxia-telangiectasia (AT) Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Ataxia-telangiectasia (AT) Treatment Market Size by Country (2018-2023)
7.4 Europe Ataxia-telangiectasia (AT) Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Ataxia-telangiectasia (AT) Treatment Market Size (2018-2029)
8.2 Asia-Pacific Ataxia-telangiectasia (AT) Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Ataxia-telangiectasia (AT) Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Ataxia-telangiectasia (AT) Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Ataxia-telangiectasia (AT) Treatment Market Size (2018-2029)
9.2 Latin America Ataxia-telangiectasia (AT) Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Ataxia-telangiectasia (AT) Treatment Market Size by Country (2018-2023)
9.4 Latin America Ataxia-telangiectasia (AT) Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Ataxia-telangiectasia (AT) Treatment Market Size (2018-2029)
10.2 Middle East & Africa Ataxia-telangiectasia (AT) Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Ataxia-telangiectasia (AT) Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Ataxia-telangiectasia (AT) Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Detail
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Ataxia-telangiectasia (AT) Treatment Introduction
11.1.4 Sanofi Revenue in Ataxia-telangiectasia (AT) Treatment Business (2018-2023)
11.1.5 Sanofi Recent Development
11.2 Intrabio Ltd
11.2.1 Intrabio Ltd Company Detail
11.2.2 Intrabio Ltd Business Overview
11.2.3 Intrabio Ltd Ataxia-telangiectasia (AT) Treatment Introduction
11.2.4 Intrabio Ltd Revenue in Ataxia-telangiectasia (AT) Treatment Business (2018-2023)
11.2.5 Intrabio Ltd Recent Development
11.3 Intas Pharmaceuticals Ltd
11.3.1 Intas Pharmaceuticals Ltd Company Detail
11.3.2 Intas Pharmaceuticals Ltd Business Overview
11.3.3 Intas Pharmaceuticals Ltd Ataxia-telangiectasia (AT) Treatment Introduction
11.3.4 Intas Pharmaceuticals Ltd Revenue in Ataxia-telangiectasia (AT) Treatment Business (2018-2023)
11.3.5 Intas Pharmaceuticals Ltd Recent Development
11.4 Sun Pharmaceutical Industries Ltd
11.4.1 Sun Pharmaceutical Industries Ltd Company Detail
11.4.2 Sun Pharmaceutical Industries Ltd Business Overview
11.4.3 Sun Pharmaceutical Industries Ltd Ataxia-telangiectasia (AT) Treatment Introduction
11.4.4 Sun Pharmaceutical Industries Ltd Revenue in Ataxia-telangiectasia (AT) Treatment Business (2018-2023)
11.4.5 Sun Pharmaceutical Industries Ltd Recent Development
11.5 Cipla Inc
11.5.1 Cipla Inc Company Detail
11.5.2 Cipla Inc Business Overview
11.5.3 Cipla Inc Ataxia-telangiectasia (AT) Treatment Introduction
11.5.4 Cipla Inc Revenue in Ataxia-telangiectasia (AT) Treatment Business (2018-2023)
11.5.5 Cipla Inc Recent Development
11.6 Eli Lilly and Company
11.6.1 Eli Lilly and Company Company Detail
11.6.2 Eli Lilly and Company Business Overview
11.6.3 Eli Lilly and Company Ataxia-telangiectasia (AT) Treatment Introduction
11.6.4 Eli Lilly and Company Revenue in Ataxia-telangiectasia (AT) Treatment Business (2018-2023)
11.6.5 Eli Lilly and Company Recent Development
11.7 Saol Therapeutics Inc
11.7.1 Saol Therapeutics Inc Company Detail
11.7.2 Saol Therapeutics Inc Business Overview
11.7.3 Saol Therapeutics Inc Ataxia-telangiectasia (AT) Treatment Introduction
11.7.4 Saol Therapeutics Inc Revenue in Ataxia-telangiectasia (AT) Treatment Business (2018-2023)
11.7.5 Saol Therapeutics Inc Recent Development
11.8 USV Private Limited
11.8.1 USV Private Limited Company Detail
11.8.2 USV Private Limited Business Overview
11.8.3 USV Private Limited Ataxia-telangiectasia (AT) Treatment Introduction
11.8.4 USV Private Limited Revenue in Ataxia-telangiectasia (AT) Treatment Business (2018-2023)
11.8.5 USV Private Limited Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
